Somatic mutations in cancer cells can generate tumour-specific neoepitopes, which are
recognized by autologous T cells in the host. As neoepitopes are not subject to central …

Although immunotherapy research to date has focused largely on T cells, there is mounting
evidence that tumour-infiltrating B cells and plasma cells (collectively referred to as tumour …

The skin serves as a physical barrier and an immunological interface that protects the body
from the external environment,–. Aberrant activation of immune cells can induce common …

The tumour microenvironment possesses mechanisms that suppress anti-tumour immunity.
Itaconate is a metabolite produced from the Krebs cycle intermediate cis-aconitate by the …

CD8+ T cells are critical mediators of cytotoxic effector function in infection, cancer and
autoimmunity. In cancer and chronic viral infection, CD8+ T cells undergo a progressive loss …

Autoimmune diseases (AIDs) are the consequence of a breach in immune tolerance,
leading to the inability to sufficiently differentiate between self and non-self. Immune …

Despite the success of PD-1 blockade in melanoma and other cancers, effective treatment
strategies to overcome resistance to cancer immunotherapy are lacking,. Here we identify …

The nature of the anti-tumor immune response changes as primary tumors progress and
metastasize. We investigated the role of resident memory (Trm) and circulating memory …

Imidazoquinoline derivatives (IMDs) and related compounds function as synthetic agonists
of Toll-like receptors 7 and 8 (TLR7/8) and one is FDA approved for topical antiviral and skin …

Hormone receptor–positive breast cancer (HR+) is immunologically cold and has not
benefited from advances in immunotherapy. In contrast, subsets of triple-negative breast …